Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

@article{Staatz2004ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation},
  author={Christine E Staatz and Susan E. Tett},
  journal={Clinical Pharmacokinetics},
  year={2004},
  volume={43},
  pages={623-653}
}
The aim of this review is to analyse critically the recent literature on the clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients.Dosage and target concentration recommendations for tacrolimus vary from centre to centre, and large pharmacokinetic variability makes it difficult to predict what concentration will be achieved with a particular dose or dosage change. Therapeutic ranges have not been based on statistical approaches. The majority of… Expand
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
TLDR
The population pharmacokinetic–pharmacogenetic model developed in de novo pediatric kidney transplant patients demonstrated that, in children, tacrolimus dosage should be based on weight, hematocrit levels, and CYP3A5 polymorphism. Expand
Population Pharmacokinetic Analysis of Tacrolimus in Adult Mexican Patients with Renal Transplant
TLDR
The population pharmacokinetic analysis identified important sources of variability in Tacrolimus pharmacokinetics and the model will help to calculate tacos dose requirements in Mexican renal transplant recipients according to specific clinical factors affecting Tacro Limus clearance and volume of distribution and it will also be useful for therapeutic drug monitoring. Expand
Population pharmacokinetics of tacrolimus in kidney transplant recipients - A model for individual dosing
TLDR
Initial dose of tacrolimus should be predicted from sex, CYP3A5 genotype, fat free mass and hematocrit, and Hematocrit is an importan t factor to predict changes in tacolimus whole blood concentrations over time. Expand
Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
TLDR
A better knowledge of the relationship between TAC whole blood and intracellular concentrations and calcineurin activity appears necessary before planning clinical trials to evaluate their potential interest as predictive biomarkers. Expand
The Impact of a Change in Tacrolimus Monitoring Immunoassay Techniques on Clinical Decision Making
because of its narrow therapeutic window, undergoes extensive and routine therapeutic drug monitoring in transplant patients. Multiple factors affect the pharmacokinetics of tacrolimus, includingExpand
Tacrolimus Pharmacokinetics in Living-Donor and Deceased-Donor Liver Transplant in Saudi Patients
TLDR
The results of the present study can be clinically used in the therapeutic drug monitoring of tacrolimus in the individualization of drug dosage and taking the appropriate clinical decisions to prevent allograft rejection. Expand
[Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
  • M. Fukudo
  • Medicine
  • Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • 2007
TLDR
The population pharmacokinetic and pharmacogenomic analysis of tacrolimus is reviewed, focusing on an efflux transporter P-glycoprotein and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and Bayesian forecasting to individualize the tacolimus dose in de novo living-donor liver transplant recipients is described. Expand
Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients
TLDR
It has been suggested that once-daily administration of tacrolimus may improve patient compliance, but further studies are required to demonstrate this and whether formulation conversion is worthwhile in the longer term. Expand
Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation
TLDR
A TAC population PK model was developed using nonlinear mixed-effects modeling to describe TAC PK during this period and may serve as a tool for TAC dose individualization as part of TDM. Expand
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.
TLDR
The PopPK of tacrolimus and empirical Bayesian estimates represent an accurate and convenient method to predict tacro Limus AUC(0-12) in paediatric liver transplant recipients, despite high between-subject variability in pharmacokinetics and patient demographics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 313 REFERENCES
Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants.
TLDR
Investigating the population pharmacokinetics of tacrolimus in pediatric liver transplant recipients and identifying factors that may explain pharmacokinetic variability may assist physicians in making individualized dosage decisions in regard to tacro Limus. Expand
Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.
  • W. Sam, M. Aw, +4 authors P. Ho
  • Medicine
  • British journal of clinical pharmacology
  • 2000
TLDR
The estimates of the pharmacokinetic parameters of tacrolimus agreed with those obtained from conventional pharmacokinetics studies and identified significant relationships in Asian paediatric liver transplant patients between the Pharmacokinetics of tacolimus and developmental characteristics of the patients. Expand
Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients
TLDR
The rate and extent of tacrolimus absorption after oral administration do not seem to be altered in paediatric patients, but oral doses need to be generally 2-fold higher than corresponding adult doses to reach similar tacolimus blood concentrations. Expand
Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation
  • C. Staatz, C. Willis, P. Taylor, S. Lynch, S. Tett
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
Patient outcomes in transplantation would improve if dosing of immunosuppressive agents was individualized and Pharmacokinetic information obtained will assist in tacrolimus dosing; however, further investigation into reasons for the pharmacokinetic variability of tacolimus is required. Expand
THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2
TLDR
The gut metabolism of tacrolimus is extensive and contributes significantly to its bioavailability, indicating that the gut metabolism in the overall bioavailability of tacolimus in a renal transplant population is significant. Expand
Tacrolimus pharmacokinetics in BMT patients
TLDR
Trough blood concentrations at 0 h and 12 h correlated well to AUC0–12 indicating that, as in solid organ transplantation, Cmin was a good index of drug exposure, and either time point can be used for therapeutic drug monitoring in patient management. Expand
The Pharmacogenetics of Immunosuppression for Organ Transplantation
TLDR
Genetic polymorphism of the multiple drug resistance gene-1 and the CYP3A5 genes have the greatest potential to influence the pharmacokinetics of immunosuppressants, and Pharmacogenetic typing offers the possibility of significant improvement in the individualization of Immunosuppressive drug prescribing with reduced rates of rejection and toxicity. Expand
Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation
TLDR
Nonlinear mixed-effect modeling was useful for analysis of pharmacokinetic characteristics of tacrolimus in LDLT patients, and the estimated population pharmacokinetics parameters can be applied for a priori dosage calculations in adult patients with LDLT. Expand
The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy
TLDR
The clinical monitoring of azathioprine, one of the first immunosuppressive agents used in transplantation, has historically been limited to monitoring complete blood counts for bone marrow suppression, however, newer techniques measuring intracellular DNA nucleotides appear to be promising. Expand
Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients
TLDR
The ELISA method used to measure tacrolimus blood concentrations in this study provides information of predictive value for managing the risk of nephrotoxicity, other toxicity, and rejection in liver transplant patients. Expand
...
1
2
3
4
5
...